NuVasive (NASDAQ: NUVA) has recently received a number of price target changes and ratings updates:

  • 9/27/2018 – NuVasive was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating. They now have a $82.00 price target on the stock, up previously from $60.00.
  • 9/25/2018 – NuVasive had its price target raised by analysts at Morgan Stanley from $55.00 to $77.00. They now have a “hold” rating on the stock.
  • 9/21/2018 – NuVasive was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 9/19/2018 – NuVasive was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 9/18/2018 – NuVasive had its price target raised by analysts at Canaccord Genuity from $70.00 to $80.00. They now have a “buy” rating on the stock.
  • 9/14/2018 – NuVasive was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 9/11/2018 – NuVasive had its price target raised by analysts at Cowen Inc from $62.00 to $80.00. They now have an “outperform” rating on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 8/21/2018 – NuVasive was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “NuVasive delivered revenues ahead of the Zacks Consensus Estimate while its earnings met the consensus mark. The company registered balanced growth in both its business wings. Also, a solid show by the international business buoys optimism. The company expects to see strong demand for new products and positive surgeon conversion efforts as its new Lateral Single-Position Surgery procedure gains traction in the market. Moreover, we are upbeat about the recently-completed consolidation of SafePassage. On the flip side, apart from lowered earnings, operating margin outlook seems disappointing. Headwinds like pricing pressure, reimbursement issues and competitive landscape are other major downsides. NuVasive has underperformed its industry over the past year.”
  • 8/16/2018 – NuVasive had its price target raised by analysts at BTIG Research to $72.00. They now have a “buy” rating on the stock.
  • 8/14/2018 – NuVasive had its price target raised by analysts at Piper Jaffray Companies to $75.00. They now have an “overweight” rating on the stock.
  • 8/10/2018 – NuVasive was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/3/2018 – NuVasive was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 8/2/2018 – NuVasive was upgraded by analysts at TheStreet from a “c+” rating to a “b-” rating.
  • 8/1/2018 – NuVasive had its price target lowered by analysts at Needham & Company LLC from $69.00 to $67.00. They now have a “buy” rating on the stock.
  • 8/1/2018 – NuVasive is now covered by analysts at BTIG Research. They set a “buy” rating on the stock.
  • 7/31/2018 – NuVasive had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $58.00 price target on the stock. They wrote, “: We maintain our Neutral rating on NUVA, but raise our PT to $58 from $54, as we see less downside risk to the stock than what we thought heading into 2Q. Although we are encouraged by the better-than-expected organic top-line growth in 2Q, we note that it is only one quarter. That said, NUVA’s 2H comps are significantly easier, particularly in the US, and suggest that NUVA could sustain organic growth at its 2Q level in 2H. NUVA’s guidance implies 2H organic growth of 6%+, a meaningful step up from 1H (+3%). Given the repeated delays in realizing GM improvement from the West Carrollton facility, we continue to see risk in NUVA’s ability to deliver on its 2018 operating margin guidance (OM).””
  • 7/30/2018 – NuVasive was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.

Shares of NASDAQ:NUVA traded up $2.22 during trading on Thursday, reaching $70.36. The stock had a trading volume of 985,505 shares, compared to its average volume of 737,807. The firm has a market cap of $3.56 billion, a PE ratio of 36.84, a P/E/G ratio of 1.90 and a beta of 0.69. NuVasive, Inc. has a fifty-two week low of $44.62 and a fifty-two week high of $72.12.

NuVasive (NASDAQ:NUVA) last posted its quarterly earnings data on Tuesday, July 31st. The medical device company reported $0.58 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.58. The business had revenue of $281.56 million during the quarter, compared to analyst estimates of $276.05 million. NuVasive had a net margin of 3.96% and a return on equity of 13.70%. equities analysts expect that NuVasive, Inc. will post 2.39 earnings per share for the current year.

Several large investors have recently bought and sold shares of NUVA. Strs Ohio increased its position in NuVasive by 45.5% during the second quarter. Strs Ohio now owns 3,200 shares of the medical device company’s stock worth $166,000 after purchasing an additional 1,000 shares during the last quarter. Sun Life Financial INC acquired a new position in NuVasive during the second quarter worth approximately $201,000. Cubist Systematic Strategies LLC acquired a new position in NuVasive during the second quarter worth approximately $221,000. Hartford Investment Management Co. acquired a new position in NuVasive during the second quarter worth approximately $245,000. Finally, Permanens Capital L.P. acquired a new position in NuVasive during the first quarter worth approximately $261,000.

NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

See Also: Google Finance Portfolio Workaround

Receive News & Ratings for NuVasive Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc and related companies with MarketBeat.com's FREE daily email newsletter.